The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
The sale is being made to obtain regulatory approval of Danaher's pending $21.4 billion acquisition of the GE Biopharma business.
Get the latest news from Illumina, TRC, Diagnomics, Danaher, BioDiscovery and Abbot for the week of 9/13/19
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
The firm replaced an existing $4 billion credit facility with a $5 billion one, and entered into a new $5 billion revolving credit facility.
In US influenza testing, providers see growth in placements within hospital emergency departments, physicians' offices, urgent care centers, and retail clinics.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.